Sandbox Reserved 1177

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 10: Line 10:
On the extracellular side of the protein is the
On the extracellular side of the protein is the
<scene name='72/721547/Hydrophobic_binding_pocket/5'>hydrophobic binding pocket</scene>.
<scene name='72/721547/Hydrophobic_binding_pocket/5'>hydrophobic binding pocket</scene>.
-
One key residue in this pocket is a Phenylalanine at position 358. The purpose of Phe358 is to take part in a network of hydrophobic stacking interactions. These interactions stabilize the Trp321 and Tyr324 residues allowing Tyr324 to interact with the C-terminal
+
One key residue in this pocket is a Phenylalanine at position 358, and its purpose is to take part in a network of hydrophobic stacking interactions. These interactions stabilize the Trp321 and Tyr324 residues allowing Tyr324 to interact with the C-terminal
<scene name='72/721547/Ligand_protein_interactions/7'>Leu13 residue of the NTS ligand</scene>
<scene name='72/721547/Ligand_protein_interactions/7'>Leu13 residue of the NTS ligand</scene>
via '''[https://en.wikipedia.org/wiki/Van_der_Waals_force Van der Waals interactions]''' .
via '''[https://en.wikipedia.org/wiki/Van_der_Waals_force Van der Waals interactions]''' .

Revision as of 03:31, 21 April 2016

An interactive view of the class A GPCR, NTSR1 (blue). This protein gets its activity from binding to the 13 amino acid ligand, NTS (red).

Drag the structure with the mouse to rotate

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 Krumm BE, White JF, Shah P, Grisshammer R. Structural prerequisites for G-protein activation by the neurotensin receptor. Nat Commun. 2015 Jul 24;6:7895. doi: 10.1038/ncomms8895. PMID:26205105 doi:http://dx.doi.org/10.1038/ncomms8895
  2. 2.0 2.1 2.2 2.3 2.4 2.5 White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, Gvozdenovic-Jeremic J, Shah P, Shiloach J, Tate CG, Grisshammer R. Structure of the agonist-bound neurotensin receptor. Nature. 2012 Oct 25;490(7421):508-13. doi: 10.1038/nature11558. Epub 2012 Oct 10. PMID:23051748 doi:http://dx.doi.org/10.1038/nature11558
  3. 3.0 3.1 3.2 3.3 Liang Y, Boules M, Li Z, Williams K, Miura T, Oliveros A, Richelson E. Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice. Neuropharmacology. 2010 Jun;58(8):1199-205. doi:, 10.1016/j.neuropharm.2010.02.015. Epub 2010 Mar 6. PMID:20211191 doi:http://dx.doi.org/10.1016/j.neuropharm.2010.02.015
  4. 4.0 4.1 4.2 Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides. 2006 Oct;27(10):2445-60. Epub 2006 Aug 2. PMID:16887236 doi:http://dx.doi.org/10.1016/j.peptides.2006.04.030
  5. 5.0 5.1 5.2 Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov. 2012 May 18;11(6):462-78. doi: 10.1038/nrd3702. PMID:22596253 doi:http://dx.doi.org/10.1038/nrd3702
Personal tools